Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 2, 2000, Pages 453-459

  Tang, Cuyue ^a   Shou, Magang ^a   Mei, Qin ^a   Rushmore, Thomas H ^a   Rodrigues, A David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DICLOFENAC; KETOCONAZOLE; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFAPHENAZOLE; TESTOSTERONE; TOLBUTAMIDE;

AEROBIC METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG SELECTIVITY; DRUG TRANSFORMATION; ENZYME MECHANISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, BLOCKING; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; ELECTRON TRANSPORT COMPLEX IV; HUMANS; HYDROXYLATION; KINETICS; MASS SPECTROMETRY; MICE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; NADP; OXIDATION-REDUCTION; PLANT PROTEINS; PYRAZOLES; SPECTROPHOTOMETRY, ULTRAVIOLET; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SULFONAMIDES;

EID: 0034014319     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Battistini B, Botting R and Bakhle YS (1994) COX-1 and COX-2: Toward the development of more selective NSAIDs. Drug News Perspect 7:501-512.
2. Boobis AR (1995) Prediction of inhibitory drug-drug interactions by studies in vitro, in Advances in Drug Metabolism in Man (Pacifici GM and Fracchia GN eds) pp 515-539, Luxembourg, Brussels.
3. Bourrie M, Meunier V, Berger Y and Fabre G (1995) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
4. Donnelly MT and Hawkey CJ (1997) COX-II inhibitors: A new generation of safer NSAIDs? Aliment Pharmacol Ther 11:227-236.
5. Gill HJ, Tjia JF, Kitteringham NR, Pirmohamed M, Back DJ and Park BK (1999) The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. Pharmacogenetics 9:43-53.
6. Goeger DE and Anderson KE (1992) Biochemical characterization of coumarin 7-hydroxylase activity in chick embryo liver microsomes. Biochem Pharmacol 43:363-369.
7. Goldstein JA and de Morais SMF (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
8. Gorski JC, Hall SD, Jones DR, VandenBranden M and Wrighton R (1994) Regio-selective biotransformation of midazolam by members of the human CYP3A subfamiiy. Biochem Pharmacol 47:1643-1653.
9. Graul A, Martel AM and Castaňer (1997) Celecoxib: Antiinflammatory cyclooxygenase-2 inhibitor. Drugs Future 22:711-714.
10. Jouzeau JY, Terlain B, Abid A, Nedelec E and Netter P (1997) Cyclooxygenase isoenzymes: How recent findings affect thinking about nonsteroidal antiinflammatory drugs. Drugs 53:563-582.
11. Karim A, Tolbert D, Burton E, Piergies A, Harper K, Paulson S, Schoenhard G, Hubbard R, Isakson P and Geis S (1997) A highly selective inhibitor of cyclooxygenase-2: Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation. Pharm Res 14:5617.
12. Kunze KL, Wienkers LC, Thummel KE and Trager WF (1996) Warfarin-fluconazole I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metab Dispos 24:414-421.
13. Lane NE (1997) Pain management in osteoarthntis: The role of COX-2 inhibitors. J Rheumatol 24:20-24.
14. Lasker JM, Wester MR, Aramsombatdee E and Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16-28.
15. Leatherbarrow RJ (1992) GraFit Version 3.0. Erithacus Software Ltd., Staines, UK.
16. Lipsky PE and Isakson PC (1997) Outcome of specific COX-2 inhibition on rheumatoid arthritis. J Rheumatol 24 (Suppl 49):9-14.
17. Mancy A, Dijols S, Poli S, Guengerich FP and Mansuy D (1996) Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9. Biochemistry 35: 16205-16212.
18. Mei Q, Tang C, Assang C, Slaughter D, Rodrigues AD, Rushmore TH and Shou M (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749-759.
19. McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, Waldman S, Bjornsson T, Spielberg S and Goldberg MR (1999) Phenotype and genotype investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther 65:348-352.
20. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
21. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
22. Noda K, Suzuki A, Okui M, Noguchi H, Nishiura M and Nishiura N (1979) Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo [b, f]thiepine (zotepine) in rat, mouse, dog and man. Arzneim-Forsch 29:1595-1600.
23. O'Neill GP, Mancini JA, Kargman S, Yergey J, Kwan MY, Falgueyret JP, Abramovitz M, Kennedy BP, Quellet M, Cromlish W, Culp S, Evans JF, Ford-Hutchinson AW and Vickers PJ (1994) Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: Inhibition by nonsteroidal antiinflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 45:245-254.
24. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY and Isakson PC (1997) Synthesis and biological evaluation of the 1,5-diarypyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluromethyl)-1H-pyrazol-1-yl]benzensulfonamide (SC-58635, Celecoxib). J Med Chem 40:1347-1365.
25. Riendeau D, Charleson S, Cromlish W, Mancini JA, Wong E and Guay J (1997) Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal antiinflammatory drug (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol 75:1088-1095.
26. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
27. 14C]Naproxen O-demethylase activity in human liver microsomes: Evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Dispos 24:126-136.
28. Schmider J, Greenblatt DJ, Harmatz JS and Shader RI (1996) Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: Application to amitriptyline N-demethylation. Br J Clin Pharmacol 41:593-604.
29. Shiraga T, Kaneko H, Iwasaki K, Tozuka Z, Suzuki A and Hata T (1999) Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica 29:217-229.
30. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC and Geis GS (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthitis and rheumatiod arthritis, and studies of gastrointestinal and platelet effects Arthritis Rheum 41:1591-1602.
31. Smith WL and DeWitt DL (1996) Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 62:167-215.
32. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin Ly, Hiratsuka A, Schmitz DA and Chu TY (1994) The demethylation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151-1156.
33. Vane JR, Bakhle YS and Bolting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97-120.
34. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS and Shader RI (1996) Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783-791.